Last reviewed · How we verify
Triostat
Triostat is a Small molecule drug developed by Seattle Children's Hospital. It is currently in Phase 3 development. Also known as: triiodothyronine.
Triostat is a manufactured form of the thyroid hormone triiodothyronine (T3), used to treat hypothyroidism and myxedema coma. It is a small molecule thyroid hormone receptor agonist, classified as an agonist.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Triostat |
|---|---|
| Also known as | triiodothyronine |
| Sponsor | Seattle Children's Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Comparison Of The Effects Of Regional Anesthesia On Brain And Carotid Artery Oxygenation In Shoulder Surgery (NA)
- Internet-based Mindfulness-based Training (iMBT) for People With Depression (NA)
- Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery (PHASE2)
- Characterization and Support of Neurodevelopmental Disorders Associated With Congenital Cardiac malfoRmations - Neonatal
- A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer (PHASE2)
- Effect of Physical Activity Program on Sedentary of Patients With Upper Aerodigestive Tract Cancer (NA)
- Paravertebral Block for Mastectomy With Immediate Reconstruction (NA)
- Novel Approaches to the Treatment of Hypothyroidism (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Triostat CI brief — competitive landscape report
- Triostat updates RSS · CI watch RSS
- Seattle Children's Hospital portfolio CI
Frequently asked questions about Triostat
What is Triostat?
Who makes Triostat?
Is Triostat also known as anything else?
What development phase is Triostat in?
Related
- Manufacturer: Seattle Children's Hospital — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: triiodothyronine
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing